ストックスクリーナーアプリを入手
0.9889
3.99%
-0.0411
アフターアワーズ：
.98
-0.0089
-0.90%
前日終値:
$1.03
開ける：
$0.9957
24時間の取引高:
157.96K
Relative Volume:
1.89
時価総額：
$4.29M
収益：
$79,300
当期純損益:
$-6.92M
株価収益率:
-0.0521
EPS:
-18.9818
ネットキャッシュフロー:
$-5.34M
1週間 パフォーマンス:
+2.95%
1か月 パフォーマンス:
+30.12%
6か月 パフォーマンス:
-53.57%
1年 パフォーマンス:
-15.48%
1日の値動き範囲:
$0.97
$1.03
1週間の範囲:
$0.97
$1.14
52週間の値動き範囲:
$0.7387
$8.9999
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
VRAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRAX
Virax Biolabs Group Ltd
|
0.9889 | 4.47M | 79,300 | -6.92M | -5.34M | -18.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 122.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 31.91B | 3.81B | -644.79M | -669.77M | -6.24 |
Virax Biolabs Group Ltd Stock (VRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-31 | 開始されました | H.C. Wainwright | Buy |
Virax Biolabs Group Ltd (VRAX) 最新ニュース
Technical Analysis: TGB Banquets and Hotels Limited (532845)Consistent wealth multiplication - Autocar Professional
Virax Biolabs Group Limited Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
Technical Analysis: SPEL Semiconductor Limited (517166)Extraordinary performance - Autocar Professional
Is Virax Biolabs Group Limited a good long term investmentSuperior trading gains - jammulinksnews.com
What analysts say about Allient Inc. stockGame-changing returns - jammulinksnews.com
AI for Trademark Infringement DetectionAlpha Stock Ideas - Newser
ICICI Prudential AMC Ltd (542631) Announces Strategic ShiftExceptional earning trajectories - jammulinksnews.com
What drives Virax Biolabs Group Limited stock priceAccelerated wealth building - Autocar Professional
Virax Biolabs receives Nasdaq minimum bid price deficiency notice - Investing.com Australia
Virax Biolabs receives Nasdaq minimum bid price deficiency notice By Investing.com - Investing.com South Africa
Virax Biolabs Gets NASDAQ Deficiency Notice: What the 180-Day Compliance Timeline Means for Investors - Stock Titan
How Virax Biolabs Group Limited stock performs during market volatilityFree Step-by-Step Investment Guide - Newser
Why ATCH stock attracts strong analyst attentionFree Consultation - Newser
Why Virax Biolabs Group Limited stock attracts strong analyst attentionFree Stock Portfolio Optimization - Newser
What makes Virax Biolabs Group Limited stock price move sharplyHigh Probability Setups - Newser
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 0.7% – Time to Buy? - Defense World
Virax Biolabs Group Full Year 2025 Earnings: Misses Expectations - simplywall.st
Virax Biolabs Announces CFO Resignation and Transition - TipRanks
FibroBiologics names new CFO after going public last year - The Business Journals
Kaival Brands Innovations Group (NASDAQ:KAVL) Trading Down 1.2% – Time to Sell? - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Up 2% – Here’s What Happened - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Trading Up 6.9% – Here’s What Happened - Defense World
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
FY2025 Earnings Estimate for VRAX Issued By HC Wainwright - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Coverage Initiated by Analysts at HC Wainwright - Defense World
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Yahoo Finance
Virax Biolabs Group Ltd.’s Innovative Diagnostics and Strategic Collaborations Justify Buy Rating - TipRanks
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update - Defense World
ELISpot and FluoroSpot Assay Market Size to Hit USD 576.59 Million by 2034 - Precedence Research
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 3.9% – What’s Next? - Defense World
Virax Biolabs Launches Clinical Study on T Cell Dysfunction - TipRanks
Virax Biolabs begins UK clinical study on T cell dysfunction - Investing.com India
Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution - StockTitan
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks
Virax Biolabs shares T-Cell dysfunction findings - Investing.com India
Virax Biolabs shares T-Cell dysfunction findings By Investing.com - Investing.com South Africa
Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results - StockTitan
Virax Biolabs to Present at World Immune Regulation Meeting - TipRanks
Can Virax's T-Cell Research at WIRM 2025 Advance Post-Infection Syndrome Treatment? - StockTitan
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 205.8% in February - The AM Reporter
Cosmos Health expands distribution of Avian Influenza kits - MSN
Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8% - Defense World
Virax Biolabs aligns with US vaccine transparency efforts By Investing.com - Investing.com South Africa
Virax Biolabs Aligns with US Health Department on Vaccine Transparency - TipRanks
How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push - StockTitan
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency - Benzinga
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Market Watch: Virax Biolabs Group Ltd (VRAX)’s Noteworthy Drop, Closing at 1.71 - The Dwinnex
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January - Armenian Reporter
Virax Biolabs Group Ltd (VRAX) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):